D-0189-2025 Class II Ongoing

Recalled by Rising Pharma Holding, Inc. — East Brunswick, NJ

FDA drug recall D-0189-2025 was initiated by Rising Pharma Holding, Inc. on Dec 30, 2024 and is designated Class II. Reason for recall: CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit. The recall status is ongoing. Affected quantity: 73,680 bottles.

Recall details

Product Type
Drugs
Report Date
Jan 15, 2025
Initiation Date
Dec 30, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
73,680 bottles

Product description

Duloxetine Delayed-Release Capsules USP 20 mg, 60 count bottles, Rx only, Distributed by: Rising Pharm Holdings, Inc., East Brunswick, NJ NDC 57237-017-60

Reason for recall

CGMP Deviations; Presence of N-nitroso-duloxetine impurity above recommended interim limit.

Distribution pattern

Nationwide

Code information

Lot # DT2023003A, DT2023007A, DT2023008A, exp. date Jan-25

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0189-2025
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0189-2025. Report a data issue: hello@regdatalab.com.